Quick Takeaways
- Slate Path Capital LP filed SCHEDULE 13G/A for Cue Biopharma, Inc. Common stock, par value $0.001 per share (CUE).
- Disclosed ownership: 1.4%.
- Date of event: 31 Dec 2024.
Slate Path Capital LP - 31 Dec 2024 SCHEDULE 13G/A Report for Cue Biopharma, Inc. Common stock, par value $0.001 per share (CUE)
- Filing Manager
- Slate Path Capital LP
- Reporting Manager
- Slate Path Capital LP
- Symbol
- CUE
- Shares outstanding
- 65,631,143 shares
- Disclosed Ownership
- 918,836 shares
- Ownership
- 1.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 17:00:20 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Slate Path Capital LP disclosed 1.4% ownership in Cue Biopharma, Inc. Common stock, par value $0.001 per share (CUE) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 17:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Slate Path Capital LP | 1.4% | 918,836 | 0 | 918,836 | /s/ John Metzner | By: Jades GP, LLC, General Partner, By: John Metzner, Chief Operating Officer | |
| David Greenspan | 1.4% | 918,836 | 0 | 918,836 | /s/ Jim Feeney | Jim Feeney, Attorney-In-Fact* |